Product
ARGX-113
3 clinical trials
3 indications
Indication
Immune ThrombocytopeniaIndication
Myasthenia GravisIndication
Healthy Control ParticipantsClinical trial
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle WeaknessStatus: Completed, Estimated PCD: 2022-06-23
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune ThrombocytopeniaStatus: Completed, Estimated PCD: 2019-04-09
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female SubjectsStatus: Completed, Estimated PCD: 2016-11-15